Pioglitazone for Chronic Kidney Disease
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using Dilantin or oral contraceptives due to potential drug interactions with the study drug, pioglitazone.
What data supports the effectiveness of the drug Pioglitazone for chronic kidney disease?
Research suggests that Pioglitazone, a drug that helps improve insulin sensitivity, may also protect the kidneys by reducing inflammation and oxidative stress (damage caused by free radicals) in animal models. Additionally, it has shown benefits in managing diabetes, which is often linked to kidney problems.12345
Is pioglitazone safe for humans?
How is the drug pioglitazone unique for treating chronic kidney disease?
Pioglitazone is unique because it works by activating a specific protein in the body that helps reduce kidney damage and improve kidney function, especially in conditions like diabetes. Unlike some other treatments, it enhances the body's antioxidative capacity and reduces harmful blood vessel growth in the kidneys.12101112
What is the purpose of this trial?
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function.The goal of this study is to determine whether a short-term treatment with pioglitazone can reduce sympathetic nerve impulses throughout the body in CKD patients.
Research Team
Paul J Fadel, PhD
Principal Investigator
University of Texas at Arlington
Eligibility Criteria
This trial is for men and women aged 35-70 with moderate to severe chronic kidney disease (stages 3 and 4). Participants should have a certain level of kidney function based on lab tests. People with heart failure, current smokers, those allergic to Glitazones, or with recent serious health issues like myocardial infarction or liver disease are not eligible.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Pioglitazone or placebo for 1 month to assess reduction in ADMA and sympathetic nerve activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Pioglitazone
- Placebo
Pioglitazone is already approved in United States for the following indications:
- Type 2 diabetes mellitus
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas at Arlington
Lead Sponsor
University of Texas, Southwestern Medical Center at Dallas
Collaborator